The effect of the drug resiniferatoxin on the bladder as a treatment for cases of incontinence previously unresponsive to treatment.

Phase 4

Active, not recruiting

• Conditions: Refractory idiopathic detrusor overactivity; Renal and Urogenital - Other renal and urogenital disorders; Other - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)

• Registration Number: ACTRN12612000598886
• Lead Sponsor: Pelvic Floor Unit Research Fund (St George Hospital)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-06-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

Urodynamically proven idiopathic detrusor overactivity refractory to at least two anticholinergic treatments for 12 months

Exclusion Criteria

Pure stress incontinence, current bacterial cystitis, neurological disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency volume chart (Voids per day/night)[Prior to commencement, 1 month and 3 months after resiniferatoxin treatment];International Consultation on Incontinence Questionnaire (ICIQ)[Prior to commencement, 1 month and 3 months after resiniferatoxin treatment];Urogenital Distress Inventory (UDI)[Prior to commencement, 1 month and 3 months after treatment with resiniferatoxin]

Secondary Outcome Measures

Name	Time	Method
24 hour Pad testing (grams of leakage per 24 hours)[Prior to commencement, 1 month and 3 months after resiniferatoxin treatment];Incontinence Impact Questionnaire (IIQ)[Prior to commencement, 1 month and 3 months after resiniferatoxin treatment]